Mepolizumab alters gene regulatory networks of nasal airway type-2 and epithelial inflammation in urban children with asthma
Mepolizumab (anti-IL5 therapy) reduces asthma exacerbations in urban children with exacerbation-prone eosinophilic asthma. We previously utilized nasal transcriptomics to identify inflammatory pathways (gene co-expression modules) associated with asthma exacerbations despite this therapy. In this study, we applied differential gene correlation analysis on these targeted gene co-expression modules to gain better insight into the treatment effects on correlation structure within gene networks. Mepolizumab treatment resulted in loss of correlation amongst eosinophil-specific genes but conservation and even strengthening of correlation amongst mast cell-specific genes, T2 cytokines, and airway epithelial inflammatory genes. Notably, mepolizumab induced significant gain in correlation of genes associated with multiple aspects of airway epithelial inflammation including those related to extracellular matrix production and nitric oxide synthesis, and this change was associated with a poor clinical response to mepolizumab. These findings highlight that using differential gene correlation analysis offers insight into the molecular regulatory effects of treatment on gene interactions and may lead to better understanding of disease mechanisms and therapeutic responses. ClinicalTrials.gov ID: NCT03292588.
Authors
- Agustin Calatroni (ORCID: https://orcid.org/0000-0002-1738-5176)
- Kimberly A. Dill‐McFarland (ORCID: https://orcid.org/0000-0003-1481-7065)
- Daniel J. Jackson (ORCID: https://orcid.org/0000-0001-6938-2690)
- Gurjit K. Khurana Hershey (ORCID: https://orcid.org/0000-0001-6663-977X)
- Courtney L. Gaberino (ORCID: https://orcid.org/0000-0002-2383-760X)
- Edward M. Zoratti (ORCID: https://orcid.org/0000-0002-2626-0682)
- R. Max Segnitz (ORCID: https://orcid.org/0000-0001-9806-259X)
- William W. Busse (ORCID: https://orcid.org/0000-0003-2591-4696)
- Matthew C. Altman (ORCID: https://orcid.org/0000-0002-1784-8505)
- Meyer Kattan (ORCID: https://orcid.org/0000-0001-5533-9368)
- Leonard B. Bacharier (ORCID: https://orcid.org/0000-0003-0432-2704)
- Abigail Lang (ORCID: https://orcid.org/0000-0002-0186-691X)
- Alkis Togias (ORCID: https://orcid.org/0000-0001-9009-5717)
- Stephen J. Teach (ORCID: https://orcid.org/0000-0001-9870-6519)
- Jeffrey R. Stokes (ORCID: https://orcid.org/0000-0003-3000-0741)
- Robyn T. Cohen (ORCID: https://orcid.org/0000-0002-6902-3118)
- Patrice M. Becker (ORCID: https://orcid.org/0000-0002-1170-8587)
- Michael G. Sherenian (ORCID: https://orcid.org/0000-0002-2766-729X)
- Andrew H. Liu (ORCID: https://orcid.org/0009-0004-3961-869X)
- Michelle A. Gill
- Rajesh Kumar
Institutions
- Boston University (US)
- Cincinnati Children's Hospital Medical Center (US)
- Lurie Children's Hospital (US)
- National Institutes of Health (US)
- Monroe Carell Jr. Children's Hospital (US)
- Children's National (US)
- University of Wisconsin–Madison (US)
- Henry Ford Health System (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- Children's Hospital Colorado (US)
- National Institute of Allergy and Infectious Diseases (US)
- Rho (United States) (US)
- Benaroya Research Institute
- Columbia University (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1038/s41467-025-63629-2
- Citations
- 2
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- GlaxoSmithKline
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases